Start for free
Start for free
Royalty Pharma logo

Royalty Pharma

North America, New York, United States, New York

Description

Industry leader in investing in marketed and late stage biopharmaceutical products

Investor Profile

Royalty Pharma has made 14 investments, with 5 in the past 12 months and 86% as lead.

Stage Focus

  • Post Ipo Debt (43%)
  • Post Ipo Equity (43%)
  • Series C (7%)
  • Private Equity (7%)

Country Focus

  • United States (93%)
  • Israel (7%)

Industry Focus

  • Biotechnology
  • Health Care
  • Clinical Trials
  • Biopharma
  • Therapeutics
  • Pharmaceutical
  • Medical
  • Alternative Medicine
  • Manufacturing
  • Medical Device
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Royalty Pharma frequently co-invest with?

Eli Lilly & Company Foundation
Eli Lilly & Company Foundation
North America, Indiana, United States, Indianapolis
Co-Investments: 1
Catalio Capital Management
Catalio Capital Management
North America, New York, United States, New York
Co-Investments: 1
General Catalyst
General Catalyst
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Kearny Venture Partners
Kearny Venture Partners
North America, California, United States, San Francisco
Co-Investments: 1
Braidwell
Braidwell
North America, Connecticut, United States, Stamford
Co-Investments: 1
CC
Checkpoint Capital
North America, Texas, United States, Austin
Co-Investments: 1
Deep Track Capital
Deep Track Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 1
Marshall Wace
Marshall Wace
Europe, England, United Kingdom, London
Co-Investments: 1
Logos Capital
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 1
Janus Henderson Investors
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 1

What are some of recent deals done by Royalty Pharma?

Syndax Pharmaceuticals

Waltham, Massachusetts, United States

Syndax Pharmaceuticals focuses on developing an HDAC inhibitor for solid tumors and hematological tumors.

BiotechnologyClinical TrialsHealth CarePharmaceutical
Post Ipo DebtNov 4, 2024
Amount Raised: $350,000,000
Ascendis Pharma

Palo Alto, California, United States

Ascendis Pharma built a high-value pipeline that aims to change the clinical treatment paradigms.

BiotechnologyClinical TrialsHealth Care
Post Ipo DebtSep 3, 2024
Amount Raised: $150,000,000
Elektrofi

Boston, Massachusetts, United States

Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience.

Alternative MedicineBiotechnologyTherapeutics
Series CAug 22, 2024
Amount Raised: $112,250,000
Cytokinetics

South San Francisco, California, United States

Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.

BiopharmaBiotechnologyHealth Care
Post Ipo DebtMay 22, 2024
Amount Raised: $50,000,000
Cytokinetics

South San Francisco, California, United States

Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.

BiopharmaBiotechnologyHealth Care
Post Ipo EquityMay 22, 2024
Amount Raised: $550,000,000
Teva Pharmaceuticals

Tel Aviv, Tel Aviv, Israel

Teva Pharmaceuticals is a pharmaceutical company that develops generic and innovative medicines.

BiopharmaHealth CareMedicalPharmaceutical
Post Ipo EquityNov 13, 2023
Amount Raised: $100,000,000
Ascendis Pharma

Palo Alto, California, United States

Ascendis Pharma built a high-value pipeline that aims to change the clinical treatment paradigms.

BiotechnologyClinical TrialsHealth Care
Post Ipo DebtSep 5, 2023
Amount Raised: $150,000,000
Cytokinetics

South San Francisco, California, United States

Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.

BiopharmaBiotechnologyHealth Care
Post Ipo DebtJul 1, 2022
Amount Raised: $450,000,000
Blueprint Medicines

Cambridge, Massachusetts, United States

Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.

BioinformaticsBiotechnologyHealth CareMedical
Post Ipo EquityJun 30, 2022
Amount Raised: $1,250,000,000
ApiJect

Stamford, Connecticut, United States

ApiJect offers a technology platform that makes injectable medicines safe and available for everyone.

Health CareManufacturingMedical Device
Private EquityMay 18, 2022
Amount Raised: $111,000,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator